Evommune, Inc. EVMN
Evommune, Inc. (NYSE: EVMN) is an immunology/inflammation drug developer. Its lead program, EVO756, is in Phase 2 for Moderate-to-severe atopic dermatitis. Its next catalyst on record is EVO301: Phase 2b commencement (Q2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EVO301 — Phase 2b commencement (Q2 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EVO756 (oral MRGPRX2 antagonist) - atopic dermatitis Phase 2b | Atopic dermatitis | small molecule | Phase 2 |
| EVO756 - migraine prophylaxis Phase 2b | Refractory migraine | small molecule | Phase 2 |
| EVO756 - chronic spontaneous urticaria | CSU | small molecule | Phase 2 |
| EVO301 (IL-18 binding protein, licensed from AprilBio) | Inflammatory disease (ulcerative colitis among initial focus areas) | protein/peptide | Phase 1 |
Recent results and decisions
- Aug 6, 2026started Global Phase 2b dose-ranging migraine prophylaxis trial (~330 patients) initiated July 2026; top-line data expected 2027.
In July 2026, the Company initiated a global randomized, double-blind, placebo-controlled Phase 2b dose-ranging clinical trial in migraine prophylaxis.
Filing - Aug 6, 2026discontinued Development of EVO756 in CSU formally discontinued following June Phase 2b miss.
Following these results, Evommune has discontinued development of EVO756 in CSU and will continue to focus development efforts on AD and migraine.
Filing - Jun 29, 2026missed Phase 2b (n=160) did not meet primary endpoint of mean UAS7 change at week 12 at any dose; company says results do not support further CSU development.
The study did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.